Glass-box biopharma decision analysis — sourced, uncertainty-native.https://cartan.is/https://cartan.is/writing/decision-sciences-early-discovery/https://cartan.is/writing/decision-sciences-early-discovery/Target prioritization is the first decision on the $2B+ road to the clinic, and the hardest to do well. A look at how the target-ID playbook is changing in the AI era: not just automating the old funnel, but transforming it — and the systematic bias that scale can amplify if you're not watching.Thu, 20 Aug 2026 00:00:00 GMThttps://cartan.is/writing/pd1vegf-endgame/https://cartan.is/writing/pd1vegf-endgame/After the 2024–25 frenzy, the PD-(L)1×VEGF deal flow went quiet. On public data, waiting dominates. But the deals that will define this class are being shaped now, on private reads of the ivonescimab OS data. A map of who buys what, when, at what price — and how to get the edge.Tue, 04 Aug 2026 00:00:00 GMT